1 to 10 of 32 literature results

• Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells.

  In individuals with chronic myeloid leukemia (CML) treated by autologous hematopoietic stem cell (HSC) transplantation, malignant progenitors in the g…

  Authors: Daniela S Krause, Katherine Lazarides, Ulrich H von Andrian, Richard A Van Etten

  Source: Nature medicine. 2006 Oct

  View Full Text

• JAKing up hematopoietic proliferation.

  Mutations that deregulate proliferation and survival pathways have emerged as a common molecular theme in the pathogenesis of myeloproliferative disor…

  Authors: Kevin Shannon, Richard A Van Etten

  Source: Cancer cell. 2005 Apr

  View Full Text

• Right on target: eradicating leukemic stem cells.

  Less than a third of adults with acute myeloid leukemia (AML) are cured by current treatments, emphasizing the need for new approaches to therapy. The…

  Authors: Daniela S Krause, Richard A Van Etten

  Source: Trends in molecular medicine. 2007 Nov

  View Full Text

• Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

  Imatinib mesylate (Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia. Here we rep…

  Authors: Risto Kerkelä, Luanda Grazette, Rinat Yacobi, Cezar Iliescu, Richard Patten, Cara Beahm, Brian Walters, Sergei Shevtsov, Stéphanie Pesant, Fred J Clubb,…

  Source: Nature medicine. 2006 Aug

  View Full Text

• Bedside to bench: interfering with leukemic stem cells.

  Authors: Daniela S Krause, Richard A Van Etten

  Source: Nature medicine. 2008 May

  View Full Text

• Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.

  The Abl kinase inhibitor imatinib mesylate is the preferred treatment for Philadelphia chromosome-positive (Ph(+)) chronic myeloid leukemia (CML) in c…

  Authors: Yiguo Hu, Yuhua Liu, Shawn Pelletier, Elisabeth Buchdunger, Markus Warmuth, Doriano Fabbro, Michael Hallek, Richard A Van Etten, Shaoguang Li

  Source: Nature genetics. 2004 May

  View Full Text

• Autoinhibition of Bcr-Abl through its SH3 domain.

  Bcr-Abl is a dysregulated tyrosine kinase whose mechanism of activation is unclear. Here, we demonstrate that, like c-Abl, Bcr-Abl is negatively regul…

  Authors: Kristen M Smith, Rinat Yacobi, Richard A Van Etten

  Source: Molecular cell. 2003 Jul

  View Full Text

• Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression.

  Reactive oxygen species are involved in many cellular metabolic and signalling processes and are thought to have a role in disease, particularly in ca…

  Authors: Carola A Neumann, Daniela S Krause, Christopher V Carman, Shampa Das, Devendra P Dubey, Jennifer L Abraham, Roderick T Bronson, Yuko Fujiwara, Stuart H Orkin, Richard A Van Etten

  Source: Nature. 2003 Jul 31

  View Full Text

• Peroxiredoxin1 prevents excessive endothelial activation and early atherosclerosis.

  The peroxiredoxin (Prdx) family of antioxidant enzymes uses redox-active cysteines to reduce peroxides, lipid hydroperoxides, and peroxynitrites. Prdx…

  Authors: Janka Kisucka, Anil K Chauhan, Ian S Patten, Ayce Yesilaltay, Carola Neumann, Richard A Van Etten, Monty Krieger, Denisa D Wagner

  Source: Circulation research. 2008 Sep 12

  View Full Text

• Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations.

  8p11 myeloproliferative syndrome (EMS) is a hematopoietic stem cell disorder characterized by myeloid hyperplasia and non-Hodgkin's lymphoma with chro…

  Authors: Sergei Roumiantsev, Daniela S Krause, Carola A Neumann, Christopher A Dimitri, Frances Asiedu, Nicholas C P Cross, Richard A Van Etten

  Source: Cancer cell. 2004 Mar

  View Full Text